Business Wire

Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema

OXFORD, United Kingdom--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today ...
Business Wire

Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema

OXFORD, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing long-lasting treatments for retinal disorders, today announces that it has ...
BioWorld

FDA clears Oxular's suprachoroidal OXU-001 for entry into clinic for DME

Oxular Ltd.'s IND application has been accepted by the FDA for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). OXU-001 is dexamethasone formulated in the company's novel ...